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mmBio's lead development candidate is an influenza vaccine based on the ImmunoBody® platform technology (Figure 1 ). An ImmunoBody is a fusion of a selected immuno-dominant antigen with a cell-binding domain, the Fc fragment of human IgG1. The use of recombinant Fc fusion proteins is well documented. The Fc domain can help to solubilize hydrophobic proteins, provide a handle for easy detection and purification as well as improve half-life.
This approach has been reported for a number of candidate vaccines including HIV-1, tumor antigens, and other targets including IgG1 Fc fusion antigens made using the baculovirus expression system. [1] Antigen presentation by dendritic cells (DCs) via Fc receptormediated internalization has the potential to significantly enhance protective immunity. The fusion antigens have the ability to be processed in the endosomal pathway and presented exogenously by DCs for major histocompatibility complex (MHC) Class II presentation to induce CD4 + T helper (Th) cells. The internalized antigens could also be presented to MHC-I (also known as crosspriming) by DCs to directly activate cytotoxic T cell lymphocytes (CTLs). Thus, activation of all arms of adaptive immunity-CD4 Th cells, CD8 CTL, and B cell responses-is achieved.
The utility of influenza vaccination is well-established, but infection still results in 300-500,000 deaths worldwide in a typical year. In the UK the "at risk" groups are especially targeted. and Solvay. These systems still rely on being able to generate a seed stock of live virus and infection of cultured cells instead of eggs. The downstream processing steps of influenza virus inactivation and purification of a split vaccine remain largely the same as egg-based flu manufacturing. Alternative approaches that do not rely on live virus seed stocks have been developed in recent years. These use the genetic sequences that code for the virus surface antigens rather than the live virus itself to produce influenza antigens. [2] Influenza A and B viruses are sub-typed according to their HA, a surface glycoprotein which is the primary target for neutralizing antibodies. HA is also responsible for viral binding to host receptors, enabling entry into the host cell through endocytosis and subsequent membrane fusion. As such, HA is an important target for both drug and vaccine development, and ImmBio's influenza vaccine product is a HA-Fc recombinant fusion protein. The benefit of the Fc antigen targeting (highlighted in Figure 1 ) is the potential to elicit longlived T cell help for antibody responses which has relevance for a potential pandemic. Fc-mediated antigen presentation could be especially important in the elderly, leading to better CTL responses.
In developing this product, the choice of expression system to use for production had four key considerations: 1) Speed: Can it meet the annual production cycle for a seasonal flu vaccine or respond to an emergent pandemic?
2) Function: Does the system express an efficacious product? (The HA requires correct folding, and the Fc requires glycosylation for receptor binding.)
3) Cost: How does the cost compare to current marketed influenza vaccines? 4) Facilities: Are large-scale GMP manufacturing processes and regulatory experience available?
This analysis (Table 1) shows that the insect cell-Baculovirus Expression Vector System (BEVS) has the ideal potential requirements of speed, ability to produce functional antigens, competitive costs to current egg-based processes, and large-scale GMP manufacturing has been demonstrated.
Recombinant baculoviruses can be constructed in weeks instead of the several months needed to generate hightitered seed stocks of influenza and, unlike mammalian or insect stable cell lines, do not require a period of selection and expansion before production can begin. The yields of similar proteins are expected to be uniform, and because of the efficiency of the BEVS technology, the scale of commercial manufacturing should be competitive with other cell-based systems being developed for influenza vaccines. Cervarix®, the new GlaxoSmithKline (GSK) vaccine for human papillomavirus, is manufactured using baculovirus technology, as is Protein Science Corporation's trivalent seasonal influenza candidate vaccine, FluBlØk™, which consists of three recombinant hemagglutinin (rHA) proteins.
Insect cells have been shown to have glycosylation pathways that are fundamentally different to higher eukaryotes or mammalian cells. [3] Mammalian N-glycans are predominantly complex with terminal sialic acid residues, whilst insect N-glycan products tend to be paucimannosidic (Man3-GlcNAC2-NAsn). The N-glycosylation capabilities of insect cells are, however, sufficient to enable Fc receptor binding, and because neuraminidase (NA) naturally removes sialic acid from HA, the glycosylated HA made in insect cells would be similar to that in egg or cell-derived vaccines.
Early product development work at ImmBio had two main objectives: 1) to test the utility of BEVS by expressing a variety of HA-Fc fusion proteins; and 2) to evaluate the efficacy of the resultant products in accepted animal models for influenza vaccines. Recombinant baculoviruses were constructed using a rapid recombination technique following co-transfection of each plasmid transfer vector with a linearized, modified form of baculoviral DNA only capable of growth following recombination. [4] Once the clinical candidate was selected a commercial source of baculovirus DNA and vector, known as flashBAC™ (Oxford Expression Technologies, UK), was utilized (Figure 2) . This system has a chitinase A gene deletion feature aimed at improving protein secretion.
Production Methods
Initial production was performed in small shake flask or wave bag cultures of Sf 9 cells using a multiplicity of infection (MOI) of one, and the supernatant was harvested after 72 hours. The secreted product, enabled by deletion of the HA trans membrane domain, was partially purified using protein A chromatography and formulated into phosphate buffered saline (PBS). Purified product was then evaluated in terms of its biological activity. The binding of influenza virus-to-host cells is mediated by the inter action of the viral HA with host cell oligosaccharide-containing terminal sialic acids. [5, 6] Red blood cells (RBCs) also express sialic acid residues and can be used to measure the agglutinating activity of influenza viruses. The haemagglutination assay can be used as a method to quantify the amount of virus present as it shows the highest dilution of virus that causes agglutination. In the assay plate, the virus binds to the RBCs and causes them to form a lattice instead of forming a 'button' at the bottom of the well. We investigated the ability of HA-Fc fusion proteins to agglutinate RBCs (Figure 3 ). This gives an indication of the binding ability of the haemagglutinin of the fusion protein compared to the native haemagglutinin of influenza virus and a simple assay format to indicate product being able to haemagglutinate RBCs.
The ability of the Fc portion of the product to specifically bind Fcγ receptors was also measured. Fcγ receptor expression on the murine RAW 264.7 cell line was determined by flow cytometry. Using antibodies against FcγR I, II or III, the data show that this cell line expresses both FcγR I and III, but not FcγR II. In contrast, the human THP-1 monocytemacrophage cell line expressed FcγR I and II but not FcγRIII. [7, 8] Using fluorescence activated cell sorting (FACS), analysis of HA-human IgG1 Fc fusion antigens demonstrated ( Figure 4 ) the ability to bind both human and murine cell lines and hence confirmed that a murine flu challenge model would be relevant to evaluate immunogenicity and efficacy of candidate vaccines.
In terms of evaluating pre-clinical efficacy, the mouse model has been used extensively for evaluating immunity to influenza induced by infection and immunization. [9] Pathogenic H5N1 avian influenza viruses also readily infect and can cause lethal disease in mice consequently, the H5N1 mouse model was an appropriate choice for evaluating our fusion proteins. [10] The study was conducted at the National Institute of Biological Standards and Control (NIBSC) South Mimms, UK. Mice were immunised with HA(H5)-Fc vaccine and, following a standard immunisation schedule, challenged with a lethal dose of A/Vietnam/1194/04 H5N1 influenza virus. Survival of mice was recorded and viral titres were measured in nasal washings from surviving mice. Figure 5 shows that only one of 15 control mice survived at 14 days post-infection, whereas the majority of HA(H5)-Fc vaccinated mice (10 of 15) survived. Importantly, for those mice that did become infected, those immunised with HA-Fc performed better than HA alone in these experiments, with the mice staying healthier for longer before the onset of symptoms. In addition, about 10x lower virus titres were measured in HA(H5)-Fc vaccinated mice compared to control mice ( Figure 5 ) demonstrating a significant effect of HA(H5)-Fc vaccination on viral shedding (and so reduced virus spread in a susceptible population).
ImmBio, in collaboration with KWS Biotest Ltd. (www.kwsbiotest.co.uk), has also developed a specific (H3N2) A/Panama/2007/99 challenge model which has clear, measurable disease and immunological parameters. We further tested our HA(H3)-Fc influenza vaccines in this homologous challenge setting and similarly showed protection against disease symptoms ( Figure 6 ).
These positive data allowed the identity of a clinical candidate to be confirmed for progression to the next stage of pre-clinical developmentthat of manufacturing scale-up. ImmBio opted to do its process development work with Eden Biodesign Ltd., operating the UK's National Biomanufacturing Centre in Liverpool.
Development of ImmBio's product for clinical evaluation requires it to not only meet regulatory standards but also to be commercially viable. The risk of viral contamination is a feature common to all biotechnology products derived from cell lines (ICH Topic Q5A [R1]). [11] Attention was therefore paid to the suitability and sourcing of the process starting materials.
The Spodoptera frugiperda Sf9 cell line adapted to grow in the protein-free and animal-origin-free medium Sf-900® III SFM was sourced from Invitrogen (UK). Cells were FIGUre 6. H3N2 murine challenge study. [11] expanded and a cGMP master cell bank (MCB) successfully created in a 90% medium/10% DMSO cyropreservation medium. The cell expansion limits were justified by assessing the yield over time using a product-specific ELISA assay. Sf9 cultures were maintained out to passage number 24 (P24) and production vessels were set up at early, mid and late time points using standard conditions. Figure 7 shows that no decrease in production levels occurred over this period, validating the use of this particular cell host for BEVS expression. Recombinant baculovirus was produced by co-transfecting Sf9 cells growing in Sf-900 III SFM with transfer plasmid DNA, incorporating the HA-Fc insert and flashBAC virus DNA. Transfection was achieved using the flashBAC system according to the manufacturer's protocol. Following a round of plaque purification, one clone was chosen and amplified to produce a P2 stock of virus. On day 7, baculovirus was harvested and clarified by centrifugation at 3,500 rpm, 5 min., 20°C. The supernatant containing the baculovirus was 0.22 µm filtered and then aliquotted into sterile cryovials. A single vial was stored at 4°C and applied to a plaque assay whilst five vials were subjected to storage at -80°C and the remaining 38 vials were snap-frozen and stored in liquid nitrogen.
The titres were calculated using data from 10 -6 dilutions in a standard plaque assay. The titres of virus stored at -80°C or in liquid nitrogen were comparable (results shown in Table 1 ) although lower than the freshly harvested virus titre of 3.7 x 10 7 that was stored at 4°C ( Table 2) .
The serum-free frozen virus stocks proved to be stable-after 3 month's storage in liquid nitrogen, the titre was 1.8 x 10 7 pfu ml -1
. The P2 stock was used to produce protein, analyzed by Western blotting, and verified as a suitable starting material for the clinical development program.
Process development work is ongoing at the 20 L scale with Eden Biodesign and the upstream part of the process defined using an MOI of 0.1 with a 72 hour har- vest point. The flow chart in Figure 8 depicts the main steps that are being investigated for the downstream purification process. A protein A capture step allows the process to be generic, in terms of the Fc binding ability of the product, with ion exchange chromatography to remove unwanted process contaminants. Two orthogonal viral removal steps are incorporated to comply with the guideline on viral safety for biotechnology investigational medicinal products (EMEA CHMP/BWP/398498) [12] that of a low pH hold and a nano filtration of the final formulated product.
Conclusion
We have been able to demonstrate the utility of BEVS for the development of ImmBio's HA-Fc fusion influenza candidate vaccines. The key benefit of the production system is the speed of manufacture within the time restrictions of seasonal influenza, and in particular, pandemic vaccine production. This is accomplished through a generic process enabled by the product design and appropriately expressed protein delivering an efficacious product. 
